糖尿病及降糖药物与胰腺癌

国际肿瘤学杂志››2018,Vol. 45››Issue (3): 183-186.doi:10.3760/cma.j.issn.1673-422X.2018.03.013

梁碧玉，何伟明，何小艺，丁元林，于海兵

523808 东莞，广东医科大学流行病与卫生统计学教研室

收稿日期:2017-12-04出版日期:2018-03-08发布日期:2018-05-16
通讯作者:于海兵 E-mail:hby616688@163.com
基金资助:
广东省科技计划（2017A020215061）；东莞市医疗卫生科技计划（201605101290）；东莞市国际科技（含港澳台）合作项目（2013508152017）；广东医科大学博士启动项目（B2017010）

Diabetes, hypoglycemic drugs and pancreatic cancer

Liang Biyu, He Weiming, He Xiaoyi, Ding Yuanlin, Yu Haibing

Department of Epidemiology and Medical Statistics, Guangdong Medical University, Dongguan 523808, China

Received:2017-12-04Online:2018-03-08Published:2018-05-16
Contact:Yu Haibing E-mail:hby616688@163.com
Supported by:
Science and Technology Program of Guangdong Province of China (2017A020215061); Medical and Health Technology Program of Dongguan of China (201605101290); International Technology (Including Hong Kong, Macao and Taiwan) Cooperation Program of Dongguan of China (2013508152017); Guangdong Medical University Doctoral Program (B2017010)

摘要/Abstract

摘要：约80%的胰腺癌患者会发生葡萄糖代谢的改变，表明糖尿病与胰腺癌的发生发展存在关联。有研究表明糖尿病及降糖药与胰腺癌的发生风险、临床表现及预后密切相关。目前研究发现，胰岛素抵抗、高胰岛素血症、胰岛素样生长因子相关蛋白的表达水平及炎症反应等是糖尿病与胰腺癌相互影响的可能机制，但其确切机制仍不明确，仍需进一步深入研究。

关键词:胰腺肿瘤,糖尿病,降糖素类,药理作用分子作用机制

Abstract:About 80% of the patients with pancreatic cancer have glucose metabolism alterations, which suggests an association between diabetes and the occurrence and development of pancreatic cancer. Studies have shown that diabetes and hypoglycemic agents are closely related to the occurrence risk, clinical manifestation and prognosis of pancreatic cancer. Recent findings demonstrate that insulin resistance, hyperinsulinemia, the expression level of insulinlike growth factor related protein and inflammatory reaction are the possible mechanisms of the interaction between diabetes and pancreatic cancer. However, the definite mechanism still remains unclear, and further researches are still needed.

Key words:Pancreatic neoplasms,Diabetes mellitus,Hypoglycins,Molecular mechanisms of pharmacological action

梁碧玉，何伟明，何小艺，丁元林，于海兵. 糖尿病及降糖药物与胰腺癌[J]. 国际肿瘤学杂志, 2018, 45(3): 183-186.

Liang Biyu, He Weiming, He Xiaoyi, Ding Yuanlin, Yu Haibing. Diabetes, hypoglycemic drugs and pancreatic cancer[J]. Journal of International Oncology, 2018, 45(3): 183-186.

参考文献

［1］ Shen H, Zhan M, Wang W, et al. Impact of diabetes mellitus on the survival of pancreatic cancer: a metaanalysis［J］. Onco Targets Ther, 2016, 9: 1679-1688. DOI: 10.2147/OTT.S95744. ［2］ Lee SH, Yoon SH, Lee HS, et al. Can metformin change the prognosis of pancreatic cancer? Retrospective study for pancreatic cancer patients with preexisting diabetes mellitus type 2［J］. Dig Liver Dis, 2016, 48(4): 435-440. DOI: 10.1016/j.dld.2015.12.006. ［3］ Xu Y, Wang L, He J, et al. Prevalence and control of diabetes in Chinese adults［J］. JAMA, 2013, 310(9): 948-959. DOI: 10.1001/jama.2013.168118. ［4］ Pang Y, Kartsonaki C, Guo Y, et al. Diabetes, plasma glucose and incidence of pancreatic cancer: a prospective study of 0.5 million Chinese adults and a metaanalysis of 22 cohort studies［J］. Int J Cancer, 2017, 140(8): 17811788. DOI: 10.1002/ijc.30599. ［5］ Er KC, Hsu CY, Lee YK, et al. Effect of glycemic control on the risk of pancreatic cancer: a nationwide cohort study［J］. Medicine (Baltimore), 2016, 95(24): e3921. DOI: 10.1097/MD.0000000000003921. ［6］ Lu Y, García Rodríguez LA, Malgerud L, et al. Newonset type 2 diabetes, elevated HbA1c, antidiabetic medications, and risk of pancreatic cancer［J］. Br J Cancer, 2015, 113(11): 16071614. DOI: 10.1038/bjc.2015.353. ［7］王慧慧, 王霄英. 胰腺癌患者的糖尿病患病率及影像表现［J］. 放射学实践, 2016, 31(2): 126-128. DOI: 10.13609/j.cnki.1000-0313.2016.02.007. ［8］王飞, 李校天. 胰腺癌与新发2型糖尿病的关系［J］. 承德医学院学报, 2016, 33(3): 203-204. DOI: 10.15921/j.cnki.cyxb.2016.03.010. ［9］周美岑, 马明磊, 李玉秀. 新发糖尿病——胰腺癌早期筛查和诊断的临床线索［J］. 中华老年多器官疾病杂志, 2016, 15(6): 418-421. DOI: 10.11915/j.issn.1671-5403.2016.06.098. ［10］ Eibl G, CruzMonserrate Z, Korc M, et al. Diabetes mellitus and obesity as risk factors for pancreatic cancer［J］. J Acad Nutr Diet, 2018， 118(4): 555-567. DOI: 10.1016/j.jand.2017.07.005. ［11］ CarrerasTorres R, Johansson M, Gaborieau V, et al. The role of obesity, type 2 diabetes, and metabolic factors in pancreatic cancer: a mendelian randomization study［J］. J Natl Cancer Inst, 2017, 109(9): 495. DOI: 10.1093/jnci/djx012. ［12］ Renehan AG, Zwahlen M, Egger M. Adiposity and cancer risk: new mechanistic insights from epidemiology［J］. Nat Rev Cancer, 2015, 15(8): 484-498. DOI: 10.1038/nrc3967. ［13］ Toriola AT, StolzenbergSolomon R, Dalidowitz L, et al. Diabetes and pancreatic cancer survival: a prospective cohortbased study［J］. Br J Cancer, 2014, 111(1): 181-185. DOI: 10.1038/bjc.2014.224. ［14］ Hwang A, Narayan V, Yang YX. Type 2 diabetes mellitus and survival in pancreatic adenocarcinoma: a retrospective cohort study［J］. Cancer, 2013, 119(2): 404-410. DOI: 10.1002/cncr.27731. ［15］ Hart PA, Law RJ, Frank RD, et al. Impact of diabetes mellitus on clinical outcomes in patients undergoing surgical resection for pancreatic cancer: a retrospective, cohort study［J］. Am J Gastroenterol, 2014, 109(9): 1484-1492. DOI: 10.1038/ajg.2014.193. ［16］ Beg MS, Dwivedi AK, Ahmad SA, et al. Impact of diabetes mellitus on the outcome of pancreatic cancer［J］. PLoS One, 2014, 9(5): e98511. DOI: 10.1371/journal.pone.0098511. ［17］郭延勋, 马士崟. 二甲双胍的抗肿瘤作用［J］. 国际肿瘤学杂志, 2015, 42(4): 281-283. DOI: 10.3760/cma.j.issn.1673-422X.2015.04.001. ［18］ Tsilidis KK, Capothanassi D, Allen NE, et al. Metformin does not affect cancer risk: a cohort study in the U.K. Clinical Practice Research Datalink analyzed like an intentiontotreat trial［J］. Diabetes Care, 2014, 37(9): 2522-2532. DOI: 10.2337/dc140584. ［19］赵太云, 王胤, 程大伟, 等. 噻唑烷二酮类对2型糖尿病并发癌症风险的荟萃分析［J］. 中华消化病与影像杂志(电子版), 2015, 5(6): 25-32. DOI: 10.3877/cma.j.issn.2095-2015.2015.06.008. ［20］ Zhang JW, Sun Q. Metformin may improve the prognosis of patients with pancreatic cancer［J］. Asian Pac J Cancer Prev, 2015, 16(9): 3937-3940. ［21］ Choi Y, Kim TY, Oh DY, et al. The impact of diabetes mellitus and metformin treatment on survival of patients with advanced pancreatic cancer undergoing chemotherapy［J］. Cancer Res Treat, 2016, 48(1): 171-179. DOI: 10.4143/crt.2014.292. ［22］ Jang WI, Kim MS, Kang SH, et al. Association between metformin use and mortality in patients with type 2 diabetes mellitus and localized resectable pancreatic cancer: a nationwide populationbased study in korea［J］. Oncotarget, 2017, 8(6): 95879596. DOI: 10.18632/oncotarget.14525. ［23］ Kordes S, Pollak MN, Zwinderman AH, et al. Metformin in patients with advanced pancreatic cancer: a doubleblind, randomised, placebocontrolled phase 2 trial［J］. Lancet Oncol, 2015, 16(7): 839-847. DOI: 10.1016/S1470-2045(15)00027-3. ［24］ Reni M, Dugnani E, Cereda S, et al. (Ir)relevance of metformin treatment in patients with metastatic pancreatic cancer: an openlabel, randomized phase Ⅱ trial［J］. Clin Cancer Res, 2016, 22(5): 1076-1085. DOI: 10.1158/1078-0432.CCR-15-1722. ［25］ Chaiteerakij R, Petersen GM, Bamlet WR, et al. Metformin use and survival of patients with pancreatic cancer: a cautionary lesson［J］. J Clin Oncol, 2016, 34(16): 1898-1904. DOI: 10.1200/JCO.2015.63.3511. ［26］ Yang YX, Rustgi AK. Impact of metformin on advanced pancreatic cancer survival: too little, too late?［J］. Clin Cancer Res, 2016, 22(5): 10311033. DOI: 10.1158/1078-0432.CCR-15-2494. ［27］ Biadgo B, Abebe M. Type 2 diabetes mellitus and its association with the risk of pancreatic carcinogenesis: a review［J］. Korean J Gastroenterol, 2016, 67(4): 168-177. DOI: 10.4166/kjg.2016.67.4.168. ［28］张晓辉, 王锦波. 糖尿病致胰腺癌的机制研究现状［J］. 中华灾害救援医学, 2016, 4(5): 281-284. DOI: 10.13919/j.issn.20956274.2016.05.013.

[1]	张洁, 范玲, 李杰, 温华, 苏媛媛, 路宁, 张明鑫.原发性胰腺淋巴瘤1例并文献复习[J]. 国际肿瘤学杂志, 2024, 51(5): 316-320.
[2]	魁国菊, 黄江宾, 张文华, 杨立民.区域淋巴结大小对胰头腺癌术后复发的影响[J]. 国际肿瘤学杂志, 2023, 50(10): 608-613.
[3]	王丽薇, 梁洪生, 杜松林, 陈志豪, 王晴, 高爱丽.阿维菌素类药物在抗肿瘤方面的研究进展[J]. 国际肿瘤学杂志, 2022, 49(6): 353-356.
[4]	严志颖, 毛逸锋, 朱颖蔚, 徐克群.癌相关成纤维细胞的异质性在靶向胰腺癌治疗中的角色[J]. 国际肿瘤学杂志, 2021, 48(5): 308-312.
[5]	中国医师协会放射肿瘤治疗医师分会.胰腺癌立体定向放疗(放射外科)指南[J]. 国际肿瘤学杂志, 2021, 48(11): 643-648.
[6]	钟扬, 何苗, 刘志, 陈建宇, 张光年, 秦龙, 李婷, 李建水.麦冬皂苷D联合沉默环氧合酶-2基因对人胰腺癌BxPC-3细胞增殖、迁移和侵袭的影响[J]. 国际肿瘤学杂志, 2021, 48(10): 583-590.
[7]	李珂珂, 孔盼盼, 易超, 王喜艳, 晏冬.淋巴样增强因子-1在胰腺导管腺癌中的表达及对预后的影响[J]. 国际肿瘤学杂志, 2021, 48(10): 608-613.
[8]	陈晓旭, 于洋, 张天雪.基于免疫相关lncRNA建立胰腺癌预后风险评估模型[J]. 国际肿瘤学杂志, 2020, 47(8): 472-479.
[9]	王雪, 纪国欣, 纪超, 杨兴升.二甲双胍对合并2型糖尿病的Ⅰ型子宫内膜癌患者预后的影响[J]. 国际肿瘤学杂志, 2020, 47(7): 404-408.
[10]	赵小玲, 孔为民.二甲双胍在子宫内膜癌中的基础与临床研究现状[J]. 国际肿瘤学杂志, 2020, 47(7): 440-443.
[11]	田春方, 沙丹.锌指蛋白与消化系统肿瘤[J]. 国际肿瘤学杂志, 2020, 47(2): 115-118.
[12]	纪周新, 贺德.微生物群与胰腺癌[J]. 国际肿瘤学杂志, 2020, 47(1): 46-50.
[13]	靳小倩,韩春,王澜.胰腺实性假乳头状瘤变异型快速进展一例[J]. 国际肿瘤学杂志, 2019, 46(4): 255-256.
[14]	李庆贺, 刘慧纯, 张家耀, 李伟.miR-200b-3p下调VEGFA调控胰腺癌细胞增殖、侵袭、迁移和凋亡的分子机制研究#br#[J]. 国际肿瘤学杂志, 2019, 46(11): 649-656.
[15]	李智,许静凯,张博.长非编码RNA在肿瘤中的作用机制[J]. 国际肿瘤学杂志, 2018, 45(4): 220-222.